BioSpace News Archive

Talaris Therapeutics, Inc. is presenting new data from its Phase 2 trial of FCR001 in living donor kidney transplant recipients in a poster at the 2019 American Transplant Congress in Boston.

Aimmune Therapeutics, Inc. presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously announced had met its primary endpoint, demonstrating the efficacy and safety of AR101 in peanut-allergic children and adolescents after six months of dose escalation and a three-month therapeutic dosing phase.

New technology innovations mark the company’s next milestones, and build on its pioneering history

22% of Patients Receiving LYNPARZA Remained Progression-Free After Two Years vs. 10% on Placebo, Following Platinum-Based Chemotherapy

First-in-human results presented for DS-1062, an investigational TROP2 targeting ADC, in patients with advanced NSCLC where no standard treatment is available

SOTIO, a biotechnology company owned by the PPF Group, presented new statistically and clinically significant results from its Phase I/II clinical trial evaluating DCVAC/LuCa, an active cellular immunotherapy product, in patients with stage IV non-small cell lung cancer.

Spectrum Pharmaceuticals, Inc. announced integrated analysis results from two Phase 3 clinical trials of ROLONTIS.

The Biotechnology Institute announced the winner of the BioGENEius Hall of Fame Award, who will be recognized next week at the 2019 BIO International Convention in Philadelphia.

Puma Biotechnology, Inc., a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology 2019 Annual Meeting in Chicago.

Data presented at ASCO 2019 showed 57% of patients alive at three years vs. 43.5% on placebo